Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Net Margin (2017 - 2025)

Historic Net Margin for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to 121.34%.

  • UroGen Pharma's Net Margin fell 274200.0% to 121.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 170.59%, marking a year-over-year decrease of 414700.0%. This contributed to the annual value of 140.35% for FY2024, which is 167400.0% down from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Net Margin is 121.34%, which was down 274200.0% from 206.24% recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Net Margin peaked at 93.93% during Q3 2024, and registered a low of 346.49% during Q1 2021.
  • In the last 5 years, UroGen Pharma's Net Margin had a median value of 160.75% in 2022 and averaged 173.72%.
  • Its Net Margin has fluctuated over the past 5 years, first skyrocketed by 82259400bps in 2021, then tumbled by -533500bps in 2025.
  • Over the past 5 years, UroGen Pharma's Net Margin (Quarter) stood at 175.91% in 2021, then rose by 9bps to 159.57% in 2022, then surged by 31bps to 110.57% in 2023, then plummeted by -38bps to 152.71% in 2024, then grew by 21bps to 121.34% in 2025.
  • Its Net Margin was 121.34% in Q3 2025, compared to 206.24% in Q2 2025 and 216.47% in Q1 2025.